Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$4.71
+1.4%
$3.94
$2.76
$13.11
$490.64M-1.4701,523 shs497,012 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$16.86
-0.9%
$14.67
$8.04
$25.88
$458.71M2.38471,680 shs151,872 shs
Evolus, Inc. stock logo
EOLS
Evolus
$7.52
-1.4%
$8.40
$5.71
$17.82
$486.72M1.071.10 million shs415,062 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.65
+6.1%
$1.52
$0.96
$3.10
$130.36M-0.23829,057 shs604,023 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
0.00%-5.31%+12.35%+34.49%-63.46%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%-3.95%+38.29%+30.85%-19.38%
Evolus, Inc. stock logo
EOLS
Evolus
0.00%+2.69%-16.61%-23.39%-51.98%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
0.00%-3.13%+6.90%-3.13%+64.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
2.6371 of 5 stars
3.60.00.00.02.21.71.3
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2.6969 of 5 stars
3.52.00.00.02.92.50.6
Evolus, Inc. stock logo
EOLS
Evolus
4.0741 of 5 stars
3.41.00.03.53.43.30.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.2181 of 5 stars
3.52.00.00.03.21.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.13
Buy$20.17328.62% Upside
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.00
Buy$50.57200.04% Upside
Evolus, Inc. stock logo
EOLS
Evolus
2.80
Moderate Buy$21.25182.58% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00811.85% Upside

Current Analyst Ratings Breakdown

Latest PLX, ALMS, ARCT, and EOLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$63.00 ➝ $54.00
8/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/14/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
8/12/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00 ➝ $49.00
8/12/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $42.00
8/6/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $18.00
8/6/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$27.00 ➝ $20.00
8/6/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$22.00
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$17.00
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$5.51 per shareN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$152.31M3.01N/AN/A$8.90 per share1.89
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M1.83N/AN/A$0.09 per share83.56
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$61.95M2.12$0.09 per share17.80$0.47 per share3.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-119.15%-92.50%11/12/2025 (Estimated)
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.07N/A5.31N/A-21.03%-30.89%-11.74%N/A

Latest PLX, ALMS, ARCT, and EOLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.11-$1.17-$0.06$0.77$1.80 million$2.67 million
8/11/2025Q2 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
6.05
6.05
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
5.90
5.90
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.27
1.86
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
15.30%
Evolus, Inc. stock logo
EOLS
Evolus
6.10%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A104.06 million61.71 millionN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.16 million23.00 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.68 million60.74 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.73 million69.00 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for PLX FY2025 Earnings?
PLX: New CFO to Take the Reins
Protalix BioTherapeutics lifts revenue on strong Elfabrio demand
Protalix Lawsuit Dismissed After Bylaws Amendment
Protalix BioTherapeutics Names SVP and CFO
Protalix BioTherapeutics welcomes new finance chief

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$4.70 +0.07 (+1.40%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$16.86 -0.16 (-0.91%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Evolus stock logo

Evolus NASDAQ:EOLS

$7.52 -0.11 (-1.44%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.64 +0.10 (+6.13%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.